[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Redhill Biophrma ADR (RDHL)

Redhill Biophrma ADR (RDHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,818
  • Shares Outstanding, K 5,191
  • Annual Sales, $ 290 K
  • Annual Income, $ -430 K
  • EBIT $ 29 M
  • EBITDA $ -8 M
  • 60-Month Beta 5.05
  • Price/Sales 16.94
  • Price/Cash Flow N/A
  • Price/Book 1.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 1,046.75
  • Most Recent Earnings N/A on 08/17/23
  • Next Earnings Date 04/09/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7851 +17.06%
on 04/21/26
1.1000 -16.45%
on 05/01/26
+0.1285 (+16.26%)
since 04/20/26
3-Month
0.7101 +29.42%
on 03/30/26
1.1000 -16.45%
on 05/01/26
-0.0640 (-6.51%)
since 02/20/26
52-Week
0.7101 +29.42%
on 03/30/26
3.3099 -72.23%
on 07/21/25
-0.9810 (-51.63%)
since 05/20/25

Most Recent Stories

More News
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

RHB-204 1  is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking...

RDHL : 0.9190 (-0.98%)
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

2025 was a year of tenacity, strategic transactions and building traction for RedHill

RDHL : 0.9190 (-0.98%)
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential...

RDHL : 0.9190 (-0.98%)
CPIX : 5.53 (+2.22%)
Joint U.S. Commercialization of RedHill's Talicia® Commences

The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and...

RDHL : 0.9190 (-0.98%)
CPIX : 5.53 (+2.22%)
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RHB-102 1  is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute...

RDHL : 0.9190 (-0.98%)
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

Resistance to venetoclax (Venclexta ®  and Venclyxto ® , Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge,...

RDHL : 0.9190 (-0.98%)
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...

RDHL : 0.9190 (-0.98%)
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RALEIGH, N.C. and TEL-AVIV, Israel , Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced...

RDHL : 0.9190 (-0.98%)
RedHill Biopharma Receives Nasdaq Staff Determination Notification

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued...

RDHL : 0.9190 (-0.98%)
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy

RDHL : 0.9190 (-0.98%)
CPIX : 5.53 (+2.22%)

Business Summary

RedHill Biopharma Ltd. is a specialty biopharmaceutical company, focused on gastrointestinal and infectious diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment is based in Raleigh, NC, and covers all areas relating...

See More

Key Turning Points

3rd Resistance Point 0.9590
2nd Resistance Point 0.9435
1st Resistance Point 0.9312
Last Price 0.9190
1st Support Level 0.9034
2nd Support Level 0.8879
3rd Support Level 0.8756

See More

52-Week High 3.3099
Fibonacci 61.8% 2.3168
Fibonacci 50% 2.0100
Fibonacci 38.2% 1.7032
Last Price 0.9190
52-Week Low 0.7101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.